Shenzhen Neptunus Bioengineering Co., Ltd. (SHE:000078)

Market Cap	8.45B +31.6%
Revenue (ttm)	27.28B -15.6%
Net Income	-1.21B
EPS	-0.46
Shares Out	2.63B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,373,553
Average Volume	63,950,568
Open	3.270
Previous Close	3.210
Day's Range	3.090 - 3.270
52-Week Range	2.080 - 5.700
Beta	0.29
RSI	34.39
Earnings Date	Apr 29, 2026

About SHE:000078

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for ho...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 8,264
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000078

Financial Performance

In 2024, SHE:000078's revenue was 30.32 billion, a decrease of -16.75% compared to the previous year's 36.42 billion. Losses were -1.19 billion, -29.38% less than in 2023.